Randomized phase II trial of cixutumumab (CIX) alone or with cetuximab (CET) for refractory recurrent/metastatic squamous cancer of head and neck (R/M-SCCHN)

被引：0
|
作者：
Glisson, Bonnie S.
Tseng, Jennifer
Marur, Shanthi
Shin, Dong M.
Murphy, Barbara A.
Cohen, Ezra E. W.
Thomas, Christopher Y.
Willey, Richard
Cosaert, Jan
William, William Nassib
Harun, Nusrat
Lee, J. Jack
Haddad, Robert I.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] MD Anderson Canc Ctr, Orlando, FL USA
[3] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[4] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[5] Vanderbilt Univ Sch Med, Deptartment Med, Nashville, TN USA
[6] Univ Chicago Med Ctr, Chicago, IL USA
[7] Wake Forest Baptist Med Ctr, Winston Salem, NC USA
[8] ImClone Syst LLC, Bridgewater, NJ USA
[9] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
[10] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6030
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Retrospective analysis of the use of cetuximab (CTX) and paclitaxel (PTX) combination in recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
    Soria Rivas, Ainara
    Rodriguez Garrote, Mercedes
    Olmedo Garcia, Maria Eugenia
    Lopez, Maria
    Garrido Lopez, Pilar
    Carrato, Alfredo
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [32] UPDATED RESULTS OF A RANDOMIZED, OPEN-PHASE II STUDY EXPLORING BIBW 2992 VERSUS CETUXIMAB IN PATIENTS WITH PLATINUM-REFRACTORY METASTATIC/RECURRENT HEAD AND NECK CANCER (SCCHN)
    Seiwert, T. Y.
    Fayette, J.
    Del Campo, J. M.
    Clement, P. M.
    Hitt, R.
    Cupissol, D.
    Degardin, M.
    Zhao, M.
    Thurm, H.
    Cohen, E.
    ANNALS OF ONCOLOGY, 2010, 21 : 316 - 316
  • [33] Cetuximab in combination with methotrexate (MTX) as first-line treatment in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): A phase Ib randomized phase II study versus single agent MTX
    Ham, J.
    Meerten, E.
    Fiets, E.
    Mc Haaglanden, F. Jeurissen
    Slingerland, M.
    van der Graaf, W. T. A.
    van Herpen, C. M. L.
    Beerepoot, L. V.
    ANNALS OF ONCOLOGY, 2018, 29
  • [34] Cilengitide with cetuximab, cisplatin, and 5-FU in recurrent and/or metastatic squamous cell cancer of the head and neck: the phase II ADVANTAGE trial
    Gauler, T. C.
    Clement, P. M.
    Peyrade, F.
    Krauss, J.
    Mesia, R.
    Remenar, E.
    Keilholz, U.
    Delord, J. P.
    Schafhausen, P.
    Erfan, J.
    Brummendorf, T. H.
    Iglesias, L.
    Bethe, U.
    Hicking, C.
    Vermorken, J. B.
    ONKOLOGIE, 2012, 35 : 193 - 194
  • [35] Cilengitide with cetuximab, cisplatin, and 5-FU in recurrent and/or metastatic squamous cell cancer of the head and neck: The ADVANTAGE phase II trial
    Vermorken, Jan Baptist
    Peyrade, Frederic
    Krauss, Juergen
    Mesia, Ricard
    Remenar, Eva
    Gauler, Thomas C.
    Keilholz, Ulrich
    Delord, Jean-Pierre
    Schafhausen, Philippe
    Erfan, Jozsef
    Brummendorf, Tim H.
    Iglesias, Lara
    Bethe, Ullrich
    de La Bourdonnaye, Guillaume
    Clement, Paul M.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [36] Phase II trial of irinotecan (Ir) plus cisplatin (CDDP) in patients with recurrent or metastatic squamous carcinoma of the head and neck (SCCHN)
    Gilbert, J.
    Cmelak, A.
    Burkey, B.
    Sinard, R.
    Yarborough, W.
    Netterville, J.
    Paty, V.
    Chung, C.
    Hudson, T.
    Murphy, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [37] Cetuximab plus platinum-based therapy first-line in recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Efficacy and safety results of a randomized phase III trial (EXTREME)
    Vermorken, J. B.
    Hitt, R.
    Geoffrois, L.
    Erfan, J.
    Kawecki, A.
    Zabolotnyy, D.
    Schueler, A.
    Knecht, R.
    Benasso, M.
    Kienzer, H.
    EJC SUPPLEMENTS, 2007, 5 (04): : 324 - 324
  • [38] TEMHEAD: a single-arm multicentre phase II study of temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO)
    Gruenwald, V.
    Keilholz, U.
    Boehm, A.
    Guntinas-Lichius, O.
    Hennemann, B.
    Schmoll, H. J.
    Ivanyi, P.
    Abbas, M.
    Lehmann, U.
    Koch, A.
    Karch, A.
    Zoerner, A.
    Gauler, T. C.
    ANNALS OF ONCOLOGY, 2015, 26 (03) : 561 - 567
  • [39] A phase II and biomarker study of an irreversible pan-human EGF receptor (HER) tyrosine kinase inhibitor, dacomitinib, in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M-SCCHN)
    Kim, Han Sang
    Kwon, Hyung Joo
    Ahn, Myung-Ju
    Kang, Byung Woog
    Sun, Jong-Mu
    Yoon, Dok-Hyun
    Park, Keon U.
    Lee, Se-Hoon
    Koh, Yoon Woo
    Kim, Se Hun
    Choi, Eun Chang
    Kim, Hye Ryun
    Kim, Hyo Song
    Kim, Joo Hang
    Cho, Byoung Chul
    CANCER RESEARCH, 2014, 74 (19)
  • [40] Cetuximab, fluorouracil (5-FU), cisplatin, and docetaxel as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Interim results of a randomized phase II clinical trial (CeFCiD).
    Knoedler, Maren
    Dietz, Andreas
    Gauler, Thomas Christoph
    Gruenwald, Viktor
    Stoehlmacher, Jan
    Knipping, Stephan
    Guntinas-Lichius, Orlando
    Frickhofen, Norbert
    Schroeder, Michael
    Maschmeyer, Georg
    Rethwisch, Volker
    Haxel, Boris
    Keilholz, Ulrich
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345